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INTRODUCTION
Cataplexy is a symptom that occurs when the muscle ten-
sion in various areas of the body is suddenly decreased invol-
untarily and lasts from few seconds to several minutes. It is a
pathognomonic symptom of narcoplepsy, generally induced
in response to laugh, excitement, anger, and other emotional
changes (1, 2). In addition, among excessive daytime sleepi-
ness, cataplexy, hypnagogic hallucination, sleep paralysis and
nocturnal sleep disorder, which are known to be a symptom
pentad of narcolepsy, cataplexy has been known to be a pre-
requisite clinical symptom required for the diagnosis of nar-
colepsy according to the International Classification of Sleep
Disorders (3). In the absence of cataplexy, the diagnosis of
broad-spectrum narcolepsy is possible by the presence of other
clinical symptoms of narcolepsy and the result of multiple
sleep latency test. On the other hand, for the diagnosis of
narrow-spectrum narcolepsy, the presence of cataplexy is essen-
tial and the narcolepsy with cataplexy is considered to be an
etiologically homogeneous disease. Especially, in cases where
cataplexy is either clinically typical or severe, the frequency
of HLA-DQB1*0602 has been shown to be higher (4, 5).
Hypocretin is a pair of neuropeptides discovered in the
hypothalamus in 1998, consisting of hypocretin-1 (Hcrt 1)
and hypocretin-2 (Hcrt 2), and it has been shown that they
bind to the G protein-coupled receptors, hypocretin-1 recep-
tor (Hcrtr 1), and hypocretin receptor-2 (Hcrtr 2), increasing
intracellular calcium (6, 7). At the time of its discovery, hy-
pocretin has been introduced as a neuropeptide that incre-
ases appetite and is involved in the regulation of body tem-
perature, endocrine function, the cardiovascular system, etc.
(8). More recently, the report that showed canine narcolepsy
is caused by a mutation in the hypocretin-2 receptor gene (9,
10), and the report that showed behavioral patterns and the
electroencephalographic findings in preprohypocretin knock-
out white rats are similar to those of narcolepsy patients (11)
draw attention to the association of hypocretin and narcolep-
sy. Subsequently, it has been shown that hypocretin nerve
cells mediate excitatory action on monoaminergic neurons
and thereby they are involved in the normal sleep awake cycle
(12). In addition, it was reported that the expression of c-fos
was increased in hypocretin neurons, during the awake peri-
od and the expression of c-fos is decreased in hypocretin neu-
rons during the NREM sleep period, indicating the associa-
tion of hypocretin and sleep regulation (13).
Until now, the mutation in the preprohypocretin gene or
the hypocretin receptor gene in human narcolepsy has not
been detected (14). However, it has been reported that in most
narcolepsy patients, 80-90% of hypocretin cells in the hypo-
thalamus were destroyed (15), and the transcription of pre-
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HLA-DQB1 Allele and Hypocretin in Korean Narcoleptics with Cataplexy
Cataplexy is one of the most pathognomonic symptoms in narcolepsy. This study
was designed to investigate the frequency of the HLA-DQB1 allele and cerebrospinal
fluid (CSF) hypocretin levels in Korean narcoleptics with cataplexy as compared
with those who do not have cataplexy. Seventy-two narcoleptics were selected based
on polysomnography and multiple sleep latency test as well as their history and
clinical symptoms at Sleep Disorders Clinic. The patients were divided into a nar-
colepsy with cataplexy group (n=56) and a narcolepsy without cataplexy group
(n=16). All patients were subjected to HLA typing to determine the frequency of
DQB1 allele and to spinal tapping to measure the level of CSF hypocretin. In cata-
plexy-positive patients, as compared with cataplexy-negative patients, the frequen-
cy of HLA-DQB1*0602 was found to be significantly high (89.3% vs. 50.0%) (p=
0.003). On the other hand, the frequency of HLA-DQB1*0601 was found to be signifi-
cantly low (0% vs. 43.8%) (p<0.001). In 48 of 56 cataplexy-positive patients (85.7
%), hypocretin levels were decreased (≤110 pg/mL). However, only 6 of 16 cata-
plexy-negative patients (37.5%) exhibited a decreased hyopcretin level (p<0.001). The
high frequency of HLA-DQB1*0602, low frequency of HLA-DQB1*0601 and low
hypocretin levels in cataplexy-positive groups suggest that cataplexy-positive nar-
colepsy might be an etiologically different disease entity from the cataplexy-negative.
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prohypocretin mRNA was significantly decreased in the brain
of narcolepsy patients (14). Along with these findings, the
report showing the concentration of hypocretin in the cere-
brospinal fluid (CSF) was measured below the detection limit
in over 80% narcoleptics (16, 17) suggests that hypocretin
deficiency may be one of the most important pathophysiologic
mechanisms of narcolepsy. 
In this regard, this study was performed on narcoleptics
diagnosed by polysomnography and multiple sleep latency
test (MSLT) to understand the pathophysiology of narcolepsy
in Korean narcolepsy patients by examining the frequency
of HLA-DQB1 allele and the concentration of CSF hypocre-
tin. In addition, this study was designed to investigate the
frequency of the HLA-DQB1 allele and CSF hypocretin lev-
els in Korean narcoleptics with cataplexy as compared with
those who have not cataplexy. 
MATERIALS AND METHODS
Subjects
From August 2003 to July 2005, among the patients report-
ing excessive daytime sleepiness, those who were suspicious
of having narcolepsy were selected, based on diagnostic cri-
teria for The International Classification of Sleep Disorders
(3), and polysomnography and MSLT were performed at Sleep
Disorders Clinic of St. Vincent’s Hospital, The Catholic Uni-
versity of Korea. All patients with a chief complaint of exces-
sive daytime sleepiness not obviously from sleep disordered
breathing (SDB), delayed sleep-phase syndrome or behavio-
rally-induced insufficient sleep syndrome were included. Sev-
enty-five subjects were selected, who had at least 2 sleep onset
REM periods (SOREMPs) on MSLT, and the mean sleep laten-
cy shorter than 5 min. And in polysomnography, they did not
have any evidence of sleep disorders that can cause excessive
daytime sleepiness such as sleep apnea syndrome, periodic limb
movement disorder, etc. Seventy-two of the seventy-five sub-
jects (96%) accepted further evaluation, including blood and
CSF tests.
Seventy-two narcoleptic patients underwent HLA typing
to derermine the DQB1 allele and spinal tapping to derermine
the level of CSF hypocretin. The study subjects were divided
into a narcolepsy with cataplexy group (n=56) and a narco-
lepsy without cataplexy group (n=16) according to the pres-
ence or absence of cataplexy. Narcoleptics were excluded if
they had a personal history of medical illness that may affect
sleep, substance or alcohol abuse, seizure disorder, definite
neurological deficit, and mental disorder that may cause sleep
abnormalities. This study was approved by the institutional
review board of the St. Vincent’s Hospital, The Catholic Uni-
versity of Korea. Informed consent was obrained according
to the Declaration of Helsinki.
Methods
All clinical symptoms of narcolepsy were collected through
a structured interview in each patient by psychiatrists who
had completed the sleep medicine course and through a sleep
questionnaire. The structured interview revealed the frequency
of excessive daytime sleepiness, cataplexy, sleep paralysis, hy-
pnagogic hallucination, and the characteristic of cataplexy. In
the questionnaire, triggering factors, duration, frequency of cat-
aplexy were included, and the Stanford Center for Narcolepsy
Sleep Inventory (18) consisting of total 146 questions was used.
Lymphocytes were isolated from the blood (2×106 cells/
mL), and 0.5 mL PCR-K buffer (10× PCR buffer 1 mL,
NP-40 40  L, Tween-20 45  L, proteinase K (20 mg/mL)
30  L, D/W 8.8 mL) was added, and dissolved by treating
at 58℃for 60 min, and treated at 95℃for 10 min, to inac-
tivate proteinase K, and DNA was extracted. To determine
the HLA-DQB1 allele, allele-specific probes were labeled with
Dig-11-dUTP using terminal transferase, each sample was
dropped on a Nylon membrane, Dig-11-dUTP labeled allele-
specific probe was hybridized with the membrane dropped a
sample, the expression was assessed using anti-DIG antibody,
and finally the genotypes were determined.
Between 11 a.m. and 4 p.m., CSF was collected by lum-
bar puncture, and immediately stored frozen at -70℃ until
the measurement of hypocretin. Hypocretin-1 was measured
by  125I radioimmunoassay (RIA) kit (hypocretin-1: Phoenix
Pharmaceuticals, Mountain View, CA, U.S.A.). CSF was acid-
ified with the same volume of 0.1% trifluoroacetic acid (TFA),
purified using equilibriated C-18 Sep-Columns (Phoenix
Pharmaceuticals), and the columns were washed with 0.1%
TFA twice and eluted with 3 mL of the mixture of 0.1% TFA
and 60% acetonitrile (HPLC grade). The eluted solution was
dried by applying negative pressure, and the pellets produced
were dissolved with 300  L RIA buffer. The detection limit
was 40 pg/mL, and all samples were measured in duplicate.
Statistical analyses
Statistical analysis was performed using SPSS for Windows
(Version 10.0). Demographic data, the frequency of clinical
symptoms, and the HLA-DQB1 allele frequencies were pre-
sented as the mean±standard deviation, as well as in percent-
age. These variables and the CSF hypocretin levels were ana-
lyzed by independent t-test and chi-square test. A p-value
less than 5% was considered statistically significant. 
RESULTS
Demographical characteristics
Of the total 72 patients, 47 were male patients (65.3%),
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was 7-68 yrs (mean age 26.4±11.6 yrs). The mean body mass
index was 24.2±3.7 kg/m2, and the mean duration of illness
was 9.5±8.3 yr. 
The narcolepsy with cataplexy group consisted of 34 male
patients (60.7%) and 22 female patients (39.3%). The age
distribution was 7 to 59 yrs (mean age: 25.4±10.4 yrs). The
mean body mass index was 24.5±3.7 kg/m2, and the mean
duration of illness was 9.9±8.8 yr. 
The narcolepsy without cataplexy group consisted of 13
male patients (81.3%) and 3 female patients (18.8%). The
age distribution was 8-68 yrs (mean age 29.8±14.8 yrs).
The mean body mass index was 23.1±3.8 kg/m2. The mean
duration of illness was 8.3±6.2 yr. No significant differences
were observed in demographic variables between two groups
(Table 1). 
Clinical symptoms
Excessive daytime sleepiness was shown in all 72 patients
(100%), and it was found that cataplexy was experienced in
56 patients (77.8%), hypnagogic hallucination in 40 patients
(55.6%), and sleep paralysis was experienced in 40 patients
(55.6%). 
Hypnogogic hallucination was occurring more frequently
in the narcolepsy with cataplexy group (36/56, 64.3%) than
in the narcolepsy without cataplexy group (6/16, 25.0%) with
a statistical significance (p=0.005). In addition, sleep paraly-
sis was found to be experienced more frequently in the nar-
colepsy with cataplexy group, but the difference was not sig-
nificant (34 patients among 56 patients [60.7%] vs. 6 patients
among 16 patients [37.5%]) (Table 2).
CSF hypocretin level 
The CSF hypocretin concentration was lower than 110 pg/
mL in 54 of the total 72 patients (75.0%). The hypocretin
levels were decreased (≤110 pg/mL) (19) or below the detec-
tion limit of assay (<40 pg/mL) in 48 out of 56 cataplexy-
positive patients (85.7%). In comparison, only 6 of 16 cata-
plexy-negative patients (37.5%) had a decreased hyopcretin
level (p<0.001) (Table 3). 
HLA-DQB1 Allele 
Of 72 narcoleptic patients, 58 patients (80.6%) had HLA-
DQB1*0602. HLA-DQB1*0602 was significantly more
N, Number of subjects; NS, Not significant; BMI, body mass index. Sta-
tistical analysis was done by independent t test or chi square test.
Total
(N=72)
With 
cataplexy
(N=56)
Without
cataplexy
(N=16)
p-
value
Sex, male 47 (65.3%) 34 (60.7%) 13 (81.3%) NS
female 25 (34.7%) 22 (39.3%) 3 (18.8%)
Age (yr) 26.4±11.6 25.3±10.4 29.8±14.8 NS
Mean BMI (kg/m
2) 24.2±3.7 24.5±3.7 23.1±3.8 NS
Illness duration (yr) 9.5±8.3 9.9±8.8 8.3±6.2 NS
Table 1. Demographic data of narcoleptic patients with and with-
out cataplexy
N, Number of subjects; EDS, Excessive daytime sleepiness; NS, Not
significant.
*p=0.005 by Pearson Chi Square Test.
Total
(N=72)
With 
cataplexy
(N=56)
Without
cataplexy
(N=16)
EDS 72 (100%) 56 (100%) 16 (100%)
Hypnagogic 40 (55.6%) 36 (64.3%)* 4 (25.0%)*
hallucination
Sleep paralysis 40 (55.6%) 34 (60.7%) 6 (37.5%)
Table 2. Clinical symptoms of narcoleptic patients with and with-
out cataplexy
N, Number of subjects; No., Number.
*p<0.001 by Pearson Chi Square Test.
Total
(N=72)
With 
cataplexy
(N=56)
Without
cataplexy
(N=16)
No. of subjects 54 (75.0%) 48 (85.7%)* 6 (37.5%)*
≤110 pg/mL
No. of subjects 18 (25.5%) 8 (15.4%)* 10 (62.5%)*
>110 pg/mL
Table 3. Comparison of CSF hypocretin level in narcoleptic pa-
tients with and without cataplexy
N, Number of subjects; No., Number.
*p<0.001 by Fisher’s Exact Test, 
� p<0.001 by Pearson Chi Square Test,
� p=0.001 by Fisher’s Exact Test, 
�p<0.001 by Fisher’s Exact Test.  
DQB1
allele
Total
(N=72)
Narcoleptic patients
With 
cataplexy
(N=56)
Without
cataplexy
(N=16)
Hypocretin levels
≤110
pg/mL
(N=54)
>110
pg/mL
(N=18)
0200 7 (9.7%) 7 (12.5%) 0 (0%) 6 (11.1%) 1 (5.6%)
0301 18 (25.0%) 13 (23.2%) 5 (31.3%) 14 (25.9%) 4 (22.2%)
0302 7 (9.7%) 6 (10.7%) 2 (12.5) 5 (9.3%) 2 (11.1%)
0303 10 (13.9%) 7 (12.5%) 3 (18.8%) 7 (13.0%) 3 (30.0%)
0401 10 (13.9%) 9 (16.1%) 1 (6.3%) 8 (14.8%) 2 (20.0%)
0402 3 (4.2%) 2 (3.6%) 1 (6.3%) 1 (1.9%) 2 (11.1%)
0501 6 (8.3%) 4 (7.1%) 2 (12.5%) 3 (5.6%) 3 (16.7%)
0502 2 (2.8%) 1 (1.8%) 1 (6.3%) 1 (1.9%) 1 (5.6%)
0503 8 (11.1%) 6 (10.7%) 2 (12.5%) 5 (9.3%) 3 (16.7%)
0601 7 (9.7%) 0 (0.0%)* 7 (43.8%)* 1 (1.9%)
� 6 (33.3%)
�
0602 58 (80.6%) 50 (89.3%)
� 8 (50.0%)
� 50 (92.6%)
� 8 (44.4%)
�
0603 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
0604 2 (2.8%) 2 (3.6%) 0 (0.0%) 2 (3.7%) 0 (0.0%)
0605 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%)
0609 1 (1.4%) 1 (1.8%) 0 (0.0%) 1 (1.9%) 0 (0.0%)
Table 4. Comparison of HLA-DQB1 allele in narcoleptic patients
with and without cataplexyfrequent in cataplexy-positive patients (50/56, 89.3%) than
in cataplexy-negative patients (8/16, 50.0%) (p<0.001). On
the other hand, the frequency of HLA-DQB1*0601 was
found to be significantly lower in the narcoleptics with cat-
aplexy group (0 subjects, 0% vs. 7 subjects, 43.8%) (p<0.001)
(Table 4). 
The patients with a decreased CSF hypocretin level had a
higher rate of HLA-DQB1*0602 (50/54, 92.6%) and a lower
rate of HLA-DQB1*0601 (1/54, 1.9%) than those with a
normal hypocretin level (8/18, 44.4% and 6/18, 33.3%,
respectively) with a statistical significance (p<0.001 and p=
0.001 for each comparison) (Table 4). 
DISCUSSION
In this study, 77.8% of the narcolepsy patients experienced
cataplexy, which is in line with previous studies reporting
over 70% narcolepsy patients showed cataplexy (20, 21). As
the main pathophysiology of cataplexy, the imbalance between
monoaminergic and cholinergic transmissions in the pons
has been proposed. In addition, the cholinoceptive site in the
basal forebrain has been reported to be involved in a strong
emotional stimuli (22, 23). During cataplectic episodes, mus-
cle atonia is caused by suppression of motor neurons at the
spinal level, together with the loss of deep tendon reflex, H-
reflex, and autonomic nervous symptoms such as increased
blood pressure and decreased heart rate (23, 24). During the
initial period of cataplexy, the normal wake EEG is detected,
however, when cataplexy prolongs, the EEG becomes more
of REM sleep pattern, and the patient recalls a dream (25).
Such observations support the proposal that cataplexy is an
abnormal REM sleep phenomenon. In this study, narcolep-
tics with cataplexy experienced more hypnagogic hallucina-
tion, another REM sleep-related symptom, as compared with
narcoleptics without cataplexy. This result is thought to be
a finding that confirms the association of cataplexy and REM
sleep, suggesting that the narcolepsy with cataplexy and with-
out cataplexy may be heterogeneous groups.
As has been previously reported in other populations (4, 5,
26, 27), we also found that HLA-DQB1*0602, which has
been reported to be positive in approximately 25% of the gen-
eral population, was expressed 80.6% of the narcolepsy patient
group. This is a result supporting the proposal that the HLA-
DQB1*0602 positivity is a genetic marker for narcolepsy
regardless of the racial backgrounds. In addition, the positivi-
ty of HLA-DQB1*0602 in the narcolepsy with cataplexy and
without cataplexy was 89.3% and 50.0%, respectively. This
result is also in agreement with previous reports that the HLA-
DQB1*0602 positivity is higher in narcolepsy showing typi-
cal or severe cataplexy (4, 5, 27). In addition, we found that
the HLA-DQB1*0601 allele was not expressed in the nar-
colepsy with cataplexy group, which is in agreement with the
previous hypothesis that DQB1*0601 may serve as a protec-
tive gene against narcolepsy (28, 29). This HLA-DQB1 allelic
differences between narcolepsy with cataplexy and without
cataplexy may serve as the basis of the possibility that two
groups may be etiologically heterogeneous. 
Our study also investigated the CSF hypocretin levels in all
participants. We found that the deficiency of CSF hypocretin
was noted in 75% of Korean narcoleptic, which is a result
similar to the previous studies (16, 17). In addition, similar
to previous reports that showed a low concentration of hypo-
cretin in 9 patients among 10 patients (90%) (17), 9 patients
among 11 patients (81.8%) (30), and 23 patients among 26
(88.5%) (31), our study revealed 48 patients among 56 nar-
coleptics with cataplexy (85.7%) had a hypocretin concentra-
tion either low (≤110 pg/mL) or lower than the detection
limit (40 pg/mL), while the concentration decreased only in
6 patients among 16 narcoleptics without cataplexy (37.5%).
These results raise the possibility that hypocretin deficiency
may be an important pathophysiologic mechanism in the devel-
opment of narcolepsy and also support the fact that narcolep-
sy with cataplexy and narcolepsy without cataplexy may be
different diseases regarding their causality. Also, in 54 nar-
colepsy patients with hypocretin deficiency, as compared with
narcoleptics with a normal hypocretin level (n=18), the fre-
quency of HLA-DQB1*0602 was found to be significant
high (50 subjects, 92.6% vs. 8 subjects, 44.4%) and HLA-
DQB1*0601 was found to be low (1 subjects, 1.9% vs. 6
subjects 33.3%). This suggests that the CSF hypocretin con-
centration might be related with HLA-DQB1 allele, and
HLA-DQB1*0602 and HLA-DQB1*0601 might be have
an important role in developing narcolepsy.
The limitations of our study are the absence of results from
a normal control group was the small number of narcoleptics
without cataplexy.
In summary, this is the first study in Korea that investi-
gated the association of cataplexy with HLA-DQB1 allele
and hypocretin level. The high HLA-DQB1*0602 positivi-
ty, DQB1*0601 negativity, and hypocretin deficiency in nar-
colepsy with cataplexy in our study confirms that narcolepsy
with cataplexy and narcolepsy without cataplexy are geneti-
cally and pathophysiologically different disease entities.
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